CN119080930A - Dll3靶向抗体及其用途 - Google Patents

Dll3靶向抗体及其用途 Download PDF

Info

Publication number
CN119080930A
CN119080930A CN202411174923.9A CN202411174923A CN119080930A CN 119080930 A CN119080930 A CN 119080930A CN 202411174923 A CN202411174923 A CN 202411174923A CN 119080930 A CN119080930 A CN 119080930A
Authority
CN
China
Prior art keywords
antibody
dll
antibodies
seq
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411174923.9A
Other languages
English (en)
Chinese (zh)
Inventor
J·T·普瓦里耶
C·鲁丁
J·路易斯
A·汗
D·安德鲁
X·陈
I·洛伦兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Third Hospital Treatment Research Institute
Memorial Sloan Kettering Cancer Center
Original Assignee
Third Hospital Treatment Research Institute
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Third Hospital Treatment Research Institute, Memorial Sloan Kettering Cancer Center filed Critical Third Hospital Treatment Research Institute
Publication of CN119080930A publication Critical patent/CN119080930A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202411174923.9A 2019-07-11 2020-07-08 Dll3靶向抗体及其用途 Pending CN119080930A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962872915P 2019-07-11 2019-07-11
US62/872,915 2019-07-11
PCT/US2020/041282 WO2021007371A1 (en) 2019-07-11 2020-07-08 Dll3-targeting antibodies and uses thereof
CN202080062231.9A CN114341182B (zh) 2019-07-11 2020-07-08 Dll3靶向抗体及其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080062231.9A Division CN114341182B (zh) 2019-07-11 2020-07-08 Dll3靶向抗体及其用途

Publications (1)

Publication Number Publication Date
CN119080930A true CN119080930A (zh) 2024-12-06

Family

ID=74115317

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202411174923.9A Pending CN119080930A (zh) 2019-07-11 2020-07-08 Dll3靶向抗体及其用途
CN202411174926.2A Pending CN118955717A (zh) 2019-07-11 2020-07-08 Dll3靶向抗体及其用途
CN202080062231.9A Active CN114341182B (zh) 2019-07-11 2020-07-08 Dll3靶向抗体及其用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202411174926.2A Pending CN118955717A (zh) 2019-07-11 2020-07-08 Dll3靶向抗体及其用途
CN202080062231.9A Active CN114341182B (zh) 2019-07-11 2020-07-08 Dll3靶向抗体及其用途

Country Status (13)

Country Link
US (1) US12441789B2 (https=)
EP (1) EP3997127A4 (https=)
JP (2) JP7661299B2 (https=)
KR (1) KR20220034167A (https=)
CN (3) CN119080930A (https=)
AU (1) AU2020310894A1 (https=)
BR (1) BR112022000216A2 (https=)
CA (1) CA3146566A1 (https=)
CO (1) CO2022001195A2 (https=)
IL (1) IL289585A (https=)
MX (1) MX2022000325A (https=)
PH (1) PH12022550056A1 (https=)
WO (1) WO2021007371A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2718257T3 (https=) * 2014-05-30 2018-04-14
CN119080930A (zh) * 2019-07-11 2024-12-06 纪念斯隆凯特琳癌症中心 Dll3靶向抗体及其用途
CA3204628A1 (en) * 2021-01-13 2022-07-21 John T. POIRIER Antibody-pyrrolobenzodiazepine derivative conjugate
MX2023008285A (es) * 2021-01-13 2023-09-12 Memorial Sloan Kettering Cancer Center Conjugado de anticuerpo anti-dll3-farmaco.
MX2023012614A (es) * 2021-05-08 2023-11-03 Shanghai Qilu Pharmaceutical Res And Development Centre Ltd Molecula de union contra dll3 y uso de la misma.
AU2022339815A1 (en) * 2021-09-02 2024-03-14 Memorial Hospital For Cancer And Allied Diseases Antigen recognizing receptors targeting dll3 and uses thereof
WO2023034557A1 (en) * 2021-09-02 2023-03-09 Memorial Sloan-Kettering Cancer Center Radioligand binding to anti-dll3 antibodies for pretargeted pet imaging and therapeutic uses thereof
JP2024534892A (ja) * 2021-09-02 2024-09-26 メモリアル スローン ケタリング キャンサー センター 抗ｄｌｌ３抗体及びその使用
CA3240378A1 (en) * 2021-12-23 2023-06-29 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-dll3 antibody and pharmaceutical use thereof, and antibody-drug conjugate containing anti-dll3 antibody
EP4482859A1 (en) 2022-02-27 2025-01-01 Boehringer Ingelheim International GmbH Bispecific antibodies against cd277 and a tumor-antigen
CN116003628A (zh) * 2022-08-15 2023-04-25 南京博安生物技术有限公司 靶向人dll3抗原的全人源特异性嵌合抗原受体及其应用
WO2025184421A1 (en) * 2024-02-28 2025-09-04 Juno Therapeutics, Inc. Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1838968A (zh) 2003-08-08 2006-09-27 艾伯吉尼斯公司 针对甲状旁腺激素(pth)之抗体和其用途
AU2007325872B2 (en) * 2006-11-08 2012-12-13 Macrogenics West, Inc. TES7 and antibodies that bind thereto
DK2530091T3 (en) 2010-01-29 2018-05-28 Chugai Pharmaceutical Co Ltd ANTI-DLL3 ANTIBODY
WO2012013813A1 (en) 2010-07-30 2012-02-02 Gianluca Moroncini Epitopes of the human pdgf receptor able to bind human auto-antibodies, antibodies and uses thereof
NZ626242A (en) * 2012-01-31 2017-02-24 Regeneron Pharma Anti-asic1 antibodies and uses thereof
BR112014020826A8 (pt) 2012-02-24 2017-09-19 Stem Centrx Inc Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco – anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado
CA2939941A1 (en) 2014-02-21 2015-08-27 Abbvie Stemcentrx Llc Anti-dll3 antibodies and drug conjugates for use in melanoma
UY36245A (es) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
PT3221356T (pt) 2014-11-20 2020-10-29 Hoffmann La Roche Moléculas de ligação ao antigénio biespecíficas ativadoras das células t contra folr1 e cd3
CN119080930A (zh) * 2019-07-11 2024-12-06 纪念斯隆凯特琳癌症中心 Dll3靶向抗体及其用途

Also Published As

Publication number Publication date
CN114341182B (zh) 2024-09-10
JP2025156278A (ja) 2025-10-14
AU2020310894A1 (en) 2022-02-03
CA3146566A1 (en) 2021-01-14
JP2022540611A (ja) 2022-09-16
US20220348648A1 (en) 2022-11-03
EP3997127A1 (en) 2022-05-18
US12441789B2 (en) 2025-10-14
MX2022000325A (es) 2022-03-25
BR112022000216A2 (pt) 2022-05-17
CO2022001195A2 (es) 2022-03-08
KR20220034167A (ko) 2022-03-17
PH12022550056A1 (en) 2023-04-12
CN118955717A (zh) 2024-11-15
IL289585A (en) 2022-03-01
WO2021007371A1 (en) 2021-01-14
JP7661299B2 (ja) 2025-04-14
CN114341182A (zh) 2022-04-12
EP3997127A4 (en) 2023-08-23

Similar Documents

Publication Publication Date Title
CN114341182B (zh) Dll3靶向抗体及其用途
US12441793B2 (en) CD33 antibodies and methods of using the same to treat cancer
CN114929743B (zh) 抗steap1抗体及其用途
US11555072B2 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
CN114401744B (zh) 用于治疗癌症的抗cd33抗体
US12509515B2 (en) CD22 antibodies and methods of using the same
US20250340637A1 (en) Cd3 targeting antibodies and uses thereof
US12195554B2 (en) Anti-polysialic acid antibodies and uses thereof
US20220242967A1 (en) Anti-glypican-3 antibodies and uses thereof
US20260042860A1 (en) Anti-cd24 antibodies and uses thereof
RU2839959C2 (ru) Dll3-нацеливающие антитела и их применения
WO2024226646A2 (en) Dlk1 -targeting antibodies and uses thereof
EA046795B1 (ru) Композиции на основе антител против a33 и способы их применения в радиоиммунотерапии

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination